VNRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.6M
+304.8%
398.7K
-59.5%
985.1K
+120.4%
447.0K
-28.7%
627.3K
Cost of Revenue
0
0
0
0
0
Gross Profit
1.6M
+304.8%
398.7K
-59.5%
985.1K
+120.4%
447.0K
-28.7%
627.3K
Operating Expenses
4.9M
+8.6%
4.6M
-28.1%
6.3M
+20.3%
5.3M
-8.1%
5.7M
R&D
2.0M
+10.5%
1.8M
-36.9%
2.9M
+15.6%
2.5M
+8.0%
2.3M
SG&A
3.0M
+7.4%
2.8M
-20.9%
3.5M
+24.5%
2.8M
-18.7%
3.4M
Operating Income
-3334137
+19.8%
-4155983
+22.3%
-5348852
-11.0%
-4818384
+5.5%
-5100990
EBITDA
-3155292
+20.5%
-3967970
+22.8%
-5141481
-12.1%
-4587560
+5.5%
-4852737
Net Income
-3910589
+46.5%
-7315263
-9.1%
-6703557
-6.4%
-6302841
-16.5%
-5409791
EPS (Basic)
$-0.21
+75.3%
$-0.85
+12.4%
$-0.97
+7.6%
$-1.05
-6.1%
$-0.99
EPS (Diluted)
$-0.21
+75.3%
$-0.85
+12.4%
$-0.97
+7.6%
$-1.05
-6.1%
$-0.99
Shares (Diluted)
18.9M
+106.5%
9.2M
+33.0%
6.9M
+14.8%
6.0M
+10.8%
5.4M
VolitionRx (VNRX) — Financials